TherapeuticsMD, Inc. (TXMD) is a pioneering pharmaceutical company that is predominantly women-focused. It aims to develop products that significantly enhance women's healthcare across all stages of their lives. The company's approach is innovative; it understands that women's bodies change over time and create unique health care needs, which guides their research processes.
Incorporated in 2008 and based in Boca Raton, Florida, TherapeuticsMD operates with a steadfast commitment to delivering solutions for women's health issues. From contraception to menopause, this pharmaceutical company has designed and developed advanced hormone therapies approved by the United States Food and Drug Administration (FDA).
One of their most recognized products is IMVEXXY®, which was approved by the FDA in 2018. It is an estradiol vaginal insert designed to treat postmenopausal dyspareunia or painful sexual intercourse. Since then, the company has developed additional pivotal products like BIJUVA®, a bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. ANNOVERA® is another innovative product; it's a year-long, patient-controlled birth control method.
Their unique approach to women's health has enabled TherapeuticsMD to bridge significant gaps in the market, offering treatments that adequately consider the complexities of women's health conditions. They have strategically positioned themselves at the nexus of advanced technology and timeless female healthcare.
Araghi Farhadi, the CEO, COO and president of TherapeuticsMD, Inc., leads a team of researchers, developers and strategists, all dedicated to fostering advancements in pharmaceutical technology for women's health.
Moving forward, TherapeuticsMD is expected to continue in its role as a trailblazer in its domain; it is dedicated to creating and implementing ideas that can help millions of women worldwide. The company has managed to offer groundbreaking solutions by integrating science, technology, and innovation succinctly in creating a new standard in women's healthcare. The organization's commitment to quality, safety, and efficacy, as well as its ability to identify and pursue new opportunities, has enabled it to secure its robust market position. In a world where women's health needs aren't always made a priority, TherapeuticsMD stands as a beacon of hope for the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Shares of TherapeuticsMD Inc. (TXMD) rose 10.14% to $2.28 on Tuesday, marking its second consecutive day of gains. This performance occurred during a favorable trading session where the NASDAQ Composite Index and the Dow Jones Industrial Average also saw increases. The article highlights TXMD's outperformance compared to its competitors and the broader market indices.
TherapeuticsMD Inc. (TXMD) stock increased by 1.48% to $2.06 on a day when the broader market indices, including the NASDAQ Composite and Dow Jones Industrial Average, experienced declines. This marks the second consecutive day of gains for TherapeuticsMD Inc., demonstrating its outperformance relative to competitors during a poor trading session.
TherapeuticsMD Inc. (TXMD) stock fell by 2.90% on Monday, closing at $2.01. This underperformance occurred during a generally poor trading session where both the NASDAQ Composite Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for the company's stock.
TherapeuticsMD's Q2 2026 license revenue, primarily from the Mayne License Agreement, dropped 8.7% year over year to $864 thousand, leading to a 70% decline in net income from continuing operations. The company has fully exited research, development, and commercial operations, relying solely on this royalty stream. The article highlights the precarious position of companies that convert to a pure royalty model, as they lose the ability to generate new assets or renegotiate terms, making them highly vulnerable to revenue fluctuations.
TherapeuticsMD reported a decline in Q2 2026 license revenue and a significant drop in net income, while operating expenses slightly increased. The company continues to rely heavily on licensee performance and milestone payments, with an IMVEXXY milestone expected in Q3 2026. TherapeuticsMD is also evaluating strategic alternatives, facing risks related to revenue volatility, ongoing disputes, and liquidity concerns.
TherapeuticsMD (TXMD) reported a decline in Q2 2026 license revenue to $869,000 from $952,000 in the prior year, with net income from continuing operations also falling to $164,000. The company's operating expenses were $1.7 million, and it held $9.2 million in cash and cash equivalents. TherapeuticsMD is evaluating strategic alternatives and primarily collects royalties, having ceased R&D and commercial operations.